Evidence map›Paper›PMID 41335267›Full record

SynthesisCurrent urology reports2025

Urologic Symptom Management in Parkinson's Disease - Current Treatments and Emerging Directions - Systematic Review.

Omer Anis, Saar Anis, Myles M Reed, Daniel Teixeira-Dos-Santos, Shelley Ivary, Tyler Trump, Howard B Goldman

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Current urology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Omer Anis *Center for Urogynecology and Reconstructive Pelvic Surgery, Glickman Urological Institute, Cleveland Clinic, Cleveland, OH, USA. omerwn@gmail.com.
Saar Anis *Center for Neurological Restoration, Neurological Institute Cleveland Clinic, Cleveland, OH, USA.
Myles M ReedWeill Cornell Medical College, New York, NY, USA.
Daniel Teixeira-Dos-SantosCenter for Neurological Restoration, Neurological Institute Cleveland Clinic, Cleveland, OH, USA.
Shelley IvaryEducation Institute, Floyd D. Loop Alumni Library, Cleveland Clinic, Cleveland, OH, USA.
Tyler TrumpCenter for Urogynecology and Reconstructive Pelvic Surgery, Glickman Urological Institute, Cleveland Clinic, Cleveland, OH, USA.
Howard B GoldmanCenter for Urogynecology and Reconstructive Pelvic Surgery, Glickman Urological Institute, Cleveland Clinic, Cleveland, OH, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewThis review synthesizes current evidence on therapeutic strategies for Parkinson's disease (PD)-related overactive bladder (OAB), encompassing PD-targeted treatments, pharmacologic interventions, and advanced therapies such as neuromodulation and intravesical botulinum toxin. We address the complexity of managing lower urinary tract symptoms (LUTS) in patients with PD due to progressive neurodegeneration affecting micturition control and cognitive vulnerabilities in this population. RECENT

findingsA thorough review of available literature shows that chronic levodopa improves bladder capacity and reduces urgency, though acute dosing may worsen symptoms in advanced stages. Subthalamic nucleus-deep brain stimulation enhances bladder function and symptom scores, possibly by modulating basal ganglia-thalamocortical circuits. Anticholinergics are effective but pose cognitive risks, warranting careful use guided by anticholinergic burden assessments. In contrast, beta-3 agonists such as mirabegron offer a safer cognitive profile with emerging efficacy data. Finally, intravesical botulinum toxin and neuromodulation present promising third-line options, though data in PD remain limited, and larger trials are still needed to confirm their role. Optimal management of LUTS in PD requires individualized, stage-specific, multidisciplinary strategies balancing efficacy and cognitive safety. Further high-quality, disease-specific studies are essential to develop tailored treatment algorithms and improve quality of life in this growing patient population.

Indexed as

Lower Urinary Tract SymptomsParkinson DiseaseUrinary Bladder, OveractiveBotulinum ToxinsCholinergic AntagonistsDeep Brain StimulationHumansBotulinum ToxinsCholinergic AntagonistsIntravesical botulinum toxinLower urinary tract symptomsOveractive bladderParkinson’s diseaseSacral neuromodulationUrge urinary incontinenceβ₃-agonist

Identifiers

PMID41335267

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.